ArticleThe British journal of ophthalmology2021
Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes.
Article in The British journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05038072 (Suprachoroidal Triamcinolone Acetonide for the Treatment of Macular Edema Associated With Retinal Vein Occlusion), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Suprachoroidal Triamcinolone Acetonide for the Treatment of Macular Edema Associated With Retinal Vein Occlusion: A Pilot Study
Who cites it
23 citing papers in PubMed, 47 citations in OpenAlex.
- Safety, Tolerability and PK Characteristics of RM301B Eye Drops: A Single-Centre, Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial.Advances in therapy · 2026Trial
- Jueling Mingmu decoction combined with ranibizumab for retinal vein occlusion induced macular edema: A randomized controlled clinical trial.International ophthalmology · 2025Trial
- Early Macular Leakage Resolution Is Associated with Extended Faricimab Dosing in Retinal Vein Occlusion: A BALATON/COMINO Post Hoc Analysis.Ophthalmology and therapy · 2026Article
- Early Real-World Experience of Switching to Faricimab for Macular Oedema Secondary to Vein Occlusion.Life (Basel, Switzerland) · 2026Article
- Effectiveness and safety of intravitreal faricimab for macular oedema secondary to retinal vein occlusion: a systematic review and meta-analysis.International journal of retina and vitreous · 2026Review
- Visual acuity and retinal thickness outcomes following anti-VEGF therapy in RVO: influence of early vs. delayed treatment.BMC ophthalmology · 2026Observational
- Baseline predictors of visual response and treatment burden after ranibizumab therapy in macular edema secondary to retinal vein occlusion.Frontiers in medicine · 2026Article
- Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion.International journal of retina and vitreous · 2025Article
- Genetic engineering and the eye.Eye (London, England) · 2025Review
- Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Review
- Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion.International ophthalmology · 2023Article
- Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2023Review
- BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale.Ophthalmology science · 2023Article
- Exploring regression to the mean in visual acuities by investigating measurements at two consecutive time points in untreated fellow eyes.Eye (London, England) · 2023Article
- Suprachoroidal triamcinolone acetonide for the treatment of macular edema associated with retinal vein occlusion: a pilot study.BMC ophthalmology · 2023Article
- [Retinal vein occlusion : Intravitreal pharmacotherapies and treatment strategies for the management of macular edema].Die Ophthalmologie · 2022Review
- Real-world treatment intensities and pathways of macular edema following retinal vein occlusion in Korea from Common Data Model in ophthalmology.Scientific reports · 2022Article
- Altered synchronous neural activities in retinal vein occlusion patients: A resting-state fMRI study.Frontiers in human neuroscience · 2022Article
- Real-world outcomes of anti-vascular endothelial growth factor therapy for retinal vascular vein occlusion in Tibet, China.International journal of ophthalmology · 2022Article
- Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsTo assess visual acuity (VA) outcomes and antivascular endothelial growth factor (anti-VEGF) therapy intensity in retinal vein occlusion (RVO)-related macular oedema (ME).
methodsA retrospective study was completed in treatment-naïve patients with RVO-related ME from 2013 to 2019, using the Vestrum Health Retina Database.
resultsMean baseline age was 72.4 years and 54% were women. In 6 months, in 8876 eyes with branch retinal vein occlusion (BRVO)-related ME, after a mean of 4.5 anti-VEGF injections, VA increased by 9.4 letters (95% confidence interval (CI) for change in VA +8.94 to +9.78, p<0.001) from a baseline of 55.1 letters. In 6737 eyes with central retinal vein occlusion (CRVO)-related ME, after a mean of 4.6 anti-VEGF injections over 6 months, VA improved by 9.2 letters (95% CI +8.50 to +9.87, p<0.001) from a baseline of 37.2 letters. In 1 year, VA gain was similar (BRVO: 7.4 injections, +8.1 letters, 95% CI +7.55 to +8.57, p<0.001; CRVO: 7.6 injections, +7.1 letters, 95% CI +6.31 to +7.95, p<0.001). In 6 months and 1 year, mean letters gain increased with number of anti-VEGF injections. Patient eyes with baseline VA of 20/40 or better tended to lose VA in 1 year.
conclusionMean change in VA correlates with treatment intensity, but patients with better VA at presentation are susceptible to vision loss, reflecting a ceiling effect. Assessed with the same database, VA gains compare favourably with 1-year VA gains in neovascular age-related macular degeneration and diabetic ME, but exhibit a larger gap when compared with corresponding randomised controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.